Ryan W. Jacobs, MD

Jacobs is head of the clinical trials program for chronic lymphocytic leukemia at Levine Cancer Institute at Atrium Health.

Most recent by Ryan W. Jacobs, MD

SPONSORED CONTENT
December 06, 2023
2 min watch
Save

VIDEO: What survivorship means to patients with CLL

Healio spoke with Ryan. W. Jacobs, MD, about survivorship in CLL.

SPONSORED CONTENT
December 06, 2023
3 min watch
Save

VIDEO: Challenges in CLL management

Healio spoke with Ryan. W. Jacobs, MD, about challenges in the treatment of CLL.

SPONSORED CONTENT
December 06, 2023
1 min watch
Save

VIDEO: Potential causes, risk factors for CLL

Healio spoke with Ryan. W. Jacobs, MD, about potential causes and risk factors for developing CLL.

SPONSORED CONTENT
December 06, 2023
4 min watch
Save

VIDEO: Treatment options in CLL

Healio spoke with Ryan. W. Jacobs, MD, about treatment options available to patients with CLL.

SPONSORED CONTENT
December 06, 2023
4 min watch
Save

VIDEO: Recent advancements in CLL

Healio spoke with Ryan. W. Jacobs, MD, about recent advancements in the management of CLL.

SPONSORED CONTENT
December 01, 2023
2 min watch
Save

VIDEO: Addressing potential complications in CLL

Healio spoke with Ryan. W. Jacobs, MD, about complications that can arise in patients with CLL.

SPONSORED CONTENT
December 01, 2023
2 min watch
Save

VIDEO: Where future CLL research should focus

Healio spoke with Ryan. W. Jacobs, MD, about research needs in CLL.

SPONSORED CONTENT
December 01, 2023
2 min watch
Save

VIDEO: New treatments in the pipeline for CLL

Healio spoke with Ryan. W. Jacobs, MD, about new treatments in the pipeline for CLL.

SPONSORED CONTENT
December 01, 2023
1 min watch
Save

VIDEO: Understanding health disparities in CLL

Healio spoke with Ryan. W. Jacobs, MD, about health disparities that exist in CLL.

SPONSORED CONTENT
December 01, 2023
1 min watch
Save

VIDEO: Importance of increasing CLL awareness

Healio spoke with Ryan. W. Jacobs, MD, about the importance of increasing awareness of CLL in patients, physicians and the general public.